PDCD1 and neoplasm: Immune checkpoint engagement results in an inactivation of T cells through binding of PD-1, expressed by activated T cells, to programmed death-ligand 1 (PD-L1), expressed by cells of the tumor stroma, e.g., cancer cells and other immune cells.